Activation of NF-κB and p300/CBP potentiates cancer chemoimmunotherapy through induction of MHC-I antigen presentation

Many cancers evade immune rejection by suppressing major histocompatibility class I (MHC-I) antigen processing and presentation (AgPP). Such cancers do not respond to immune checkpoint inhibitor therapies (ICIT) such as PD-1/PD-L1 [PD-(L)1] blockade. Certain chemotherapeutic drugs augment tumor cont...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Yixuan, Bastian, Ingmar Niels, Long, Mark D., Dow, Michelle, Li, Weihua, Liu, Tao, Ngu, Rachael Katie, Antonucci, Laura, Huang, Jian Yu, Phung, Qui T., Zhao, Xi-he, Banerjee, Sourav, Lin, Xue-Jia, Wang, Hongxia, Dang, Brian, Choi, Sylvia, Karin, Daniel, Su, Hua, Ellisman, Mark H., Jamieson, Christina, Bosenberg, Marcus, Cheng, Zhang, Haybaeck, Johannes, Kenner, Lukas, Fisch, Kathleen M., Bourgon, Richard, Hernandez, Genevive, Lill, Jennie R., Liu, Song, Carter, Hannah, Mellman, Ira, Karin, Michael, Shalapour, Shabnam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: National Academy of Sciences 2021
Materias:
Biological Sciences
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7923353/
https://www.ncbi.nlm.nih.gov/pubmed/33602823
http://dx.doi.org/10.1073/pnas.2025840118

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7923353/
https://www.ncbi.nlm.nih.gov/pubmed/33602823
http://dx.doi.org/10.1073/pnas.2025840118

Ejemplares similares